CPMA Gifted $500K Legacy Grant

CPMA Gifted

$500K LEGACY GRANT

(l to r) Jon A. Hultman, DPM, MBA, CVA, Executive Director, CPMA and Bruce R. Lawrence, DPM

Following the close of the California Podiatric Medical Association’s 2022 House of Delegates on June 22 in Anaheim, CA, the doctor delegates, and alternates joined the newly elected 2022-2023 CPMA Board of Directors, guests, colleagues, family, and friends for an evening of fellowship, camaraderie, reconnecting, and renewing bonds of friendship at the Annual President’s Reception. During the celebration, CPMA Life Member Dr. Bruce Lawrence made a momentous announcement noting that he had been moved and inspired by two articles in the current issue of CPMA’s member magazine The California Podiatric Physician. The specific articles were: The Long Path to Parity: Past, Present, and Future by CPMA Executive Director Jon A. Hultman, DPM, MBA, CVA, and the other was The Quest by CPMA President Diane D. Branks, DPM, FACFAS, FACPM, RVT, which he and his spouse Janet felt provided perfect reasons and timing to create and gift the California Podiatric Medical Association with the Legacy Fund. The $500K endowment is the most significant individual gift the Association has received in its 110-year history. “This is huge,” said CPMA Executive Director Dr. Jon Hultman. “And the faith and support it shows in CPMA’s leadership and agenda is truly gratifying.” “Outstanding,” said newly elected CPMA President Holly Spohn-Gross, DPM. “I can’t find the words to express the true magnitude of this honor. It is truly positive reinforcement that we are on the right path.” Stating that the gift is seed money for a special perpetual fund directed by the CPMA Board of Directors in its ongoing muscular efforts to advance, protect and promote podiatry as it enhances the Legacy of the California Podiatric Medical Association, such as legislative initiatives - e.g. “The Quest.” Dr. Lawrence noted, “we will continue to need other CPMA members to contribute to the Legacy Fund at whatever level they are able and feel comfortable with.”

IS EXCEPTIONAL

Over 1M patients treated.1 25 years of proven bone healing. The choice of 10,000 doctors each year.2 One unique ultrasound technology.

Learn more at EXOGEN.com

Reference: 1. Bioventus LLC. Data on File, RPT-001321. 2. Bioventus LLC. Data on File, RPT-000965.

Indications for Use: The EXOGEN Ultrasound Bone Healing System is indicated for the non-invasive treatment of established nonunions* excluding skull and vertebra.

• The EXOGEN device has also been reported as effective as an adjunctive non-invasive treatment of established nonunions in patients:

• With internal or external fracture fixation hardware present. EXOGEN cannot penetrate metal and therefore should not be applied directly over hardware.

• Undergoing treatment for infection at the fracture site. EXOGEN is not intended to treat the infection.

• Believed to have diminished bone quality. EXOGEN is not intended to treat diminished bone quality.

In addition, EXOGEN is indicated for accelerating the time to a healed fracture for fresh, closed, posteriorly displaced distal radius fractures and fresh, closed or Grade I open tibial diaphysis fractures in skeletally mature individuals when these fractures are orthopaedically managed by closed reduction and cast immobilization.

There are no known contraindications for the EXOGEN device. Safety and effectiveness have not been established for individuals lacking skeletal maturity; pregnant or nursing women; patients with cardiac pacemakers; on fractures due to bone cancer; or on patients with poor blood circulation or clotting problems. Some patients may be sensitive to the ultrasound gel.

*A nonunion is considered to be established when the fracture site shows no visibly progressive signs of healing.